ResMed Inc. vs Vanguard Information Technology Index Fund ETF — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Vanguard Information Technology Index Fund ETF trades at $127.98 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 5.3× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| RMD | VGT | |
|---|---|---|
Market Cap | $31.89B | $170.20B |
Volume | 618,314 | 5,132,883 |
Sector | Health | — |
52-Week High | $275.96 | $129.79 |
52-Week Low | $182.82 | $83.59 |
Typical Hold Time | 51 Days | 129 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
VGT trades at $127.25, down 1.64% on the day but maintains a bullish technical outlook with strong moving average support. The ETF's concentration in leading technology companies like Nvidia, Apple, and Microsoft provides exposure to AI and cloud computing growth trends. Recent articles highlight VGT's historical performance of over 17% annual returns over the past two decades.
The outlook remains positive given technology sector momentum and VGT's low expense ratio advantage. Key risks include sector concentration and potential AI market slowdowns. Current technical positioning near pivot point resistance at $128 suggests potential for breakout if momentum continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →